Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Valeant Pharmaceuticals has entered into an agreement to acquire Eyetech, a privately-owned ophthalmic biotechnology company.
Subscribe to our email newsletter
The acquisition is subject to an upfront payment and potential future milestones that total significantly less than two times sales, the company said.
The transaction is expected to be immediately accretive.
Eyetech currently markets Macugen in the US, the anti-VEGF inhibitor approved for the treatment of wet age-related macular degeneration (AMD).
Valeant Chairman and CEO Michael Pearson said the acquisition of Eyetech will fit with their existing ophthalmology business, which includes a preservative free Timoptic in Ocudose and Lacrisert.